Association of metabolic and genetic heterogeneity in head and neck squamous cell carcinoma with prognostic implications: integration of FDG PET and genomic analysis.
18F-fluorodeoxyglucose
Heterogeneity
MATH
Positron emission tomography
Radiogenomics
Journal
EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946
Informations de publication
Date de publication:
21 Nov 2019
21 Nov 2019
Historique:
received:
24
07
2019
accepted:
24
09
2019
entrez:
23
11
2019
pubmed:
23
11
2019
medline:
23
11
2019
Statut:
epublish
Résumé
The linkage between the genetic and phenotypic heterogeneity of the tumor has not been thoroughly evaluated. Herein, we investigated how the genetic and metabolic heterogeneity features of the tumor are associated with each other in head and neck squamous cell carcinoma (HNSC). We further assessed the prognostic significance of those features. The mutant-allele tumor heterogeneity (MATH) score (n = 508), a genetic heterogeneity feature, and tumor glycolysis feature (GlycoS) (n = 503) were obtained from the HNSC dataset in the cancer genome atlas (TCGA). We identified matching patients (n = 33) who underwent 18F-fluorodeoxyglucose positron emission tomography (FDG PET) from the cancer imaging archive (TCIA) and obtained the following information from the primary tumor: metabolic, metabolic-volumetric, and metabolic heterogeneity features. The association between the genetic and metabolic features and their prognostic values were assessed. Tumor metabolic heterogeneity and metabolic-volumetric features showed a mild degree of association with MATH (n = 25, ρ = 0.4~0.5, P < 0.05 for all features). The patients with higher FDG PET features and MATH died sooner. Combination of MATH and tumor metabolic heterogeneity features showed a better stratification of prognosis than MATH. Also, higher MATH and GlycoS were associated with significantly worse overall survival (n = 499, P = 0.002 and 0.0001 for MATH and GlycoS, respectively). Furthermore, both MATH and GlycoS independently predicted overall survival after adjusting for clinicopathologic features and the other (P = 0.015 and 0.006, respectively). Both tumor metabolic heterogeneity and metabolic-volumetric features assessed by FDG PET showed a mild degree of association with genetic heterogeneity in HNSC. Both metabolic and genetic heterogeneity features were predictive of survival and there was an additive prognostic value when the metabolic and genetic heterogeneity features were combined. Also, MATH and GlycoS were independent prognostic factors in HNSC; they can be used for precise prognostication once validated.
Identifiants
pubmed: 31754877
doi: 10.1186/s13550-019-0563-0
pii: 10.1186/s13550-019-0563-0
pmc: PMC6872695
doi:
Types de publication
Journal Article
Langues
eng
Pagination
97Subventions
Organisme : Ministry of Education
ID : NRF-2017R1D1A1B03035556
Organisme : Ministry of Science and ICT (KR)
ID : NRF-2019M2D2A1A01058210
Organisme : Korea National Institute of Health
ID : HI18C0886
Organisme : Korea National Institute of Health
ID : HI19C0339
Références
Eur J Nucl Med Mol Imaging. 2013 Jan;40(1):133-40
pubmed: 23064544
Nucleic Acids Res. 2014 Jan;42(Database issue):D472-7
pubmed: 24243840
Cell. 2017 Feb 9;168(4):613-628
pubmed: 28187284
Nucleic Acids Res. 2005 Jan 1;33(Database issue):D428-32
pubmed: 15608231
PLoS One. 2016 Oct 13;11(10):e0164113
pubmed: 27736888
Genome Res. 2018 Nov;28(11):1747-1756
pubmed: 30341162
PLoS Med. 2015 Feb 10;12(2):e1001786
pubmed: 25668320
Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):39-49
pubmed: 21953008
Clin Nucl Med. 2016 Jan;41(1):34-40
pubmed: 26505856
Trends Cancer. 2015 Dec;1(4):231-241
pubmed: 28741514
Cancer. 2013 Aug 15;119(16):3034-42
pubmed: 23696076
PLoS One. 2016 Jul 28;11(7):e0159984
pubmed: 27467882
J Nucl Med. 2011 Nov;52(11):1690-7
pubmed: 21990577
J Nucl Med. 2002 Feb;43(2):173-80
pubmed: 11850481
Radiology. 2015 Sep;276(3):883-93
pubmed: 25897473
Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):446-454
pubmed: 30145701
Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):151-165
pubmed: 27271051
Endocrine. 2019 Feb;63(2):293-300
pubmed: 30206772
Hepatogastroenterology. 2005 Mar-Apr;52(62):486-90
pubmed: 15816463
J Nucl Med. 2014 Jun;55(6):891-7
pubmed: 24752672
Ann Nucl Med. 2008 Oct;22(8):699-705
pubmed: 18982473
J Nucl Med. 2014 Mar;55(3):414-22
pubmed: 24549286
Clin Nucl Med. 2018 Dec;43(12):887-894
pubmed: 30300200
J Nucl Med. 2015 Jan;56(1):38-44
pubmed: 25500829
Nucl Med Mol Imaging. 2013 Mar;47(1):36-43
pubmed: 24895506
Mol Cancer. 2018 Oct 17;17(1):150
pubmed: 30333042
Nat Rev Clin Oncol. 2018 Feb;15(2):81-94
pubmed: 29115304
Nat Med. 2014 Apr;20(4):342-4
pubmed: 24710377
Eur J Nucl Med Mol Imaging. 2016 Jul;43(8):1461-8
pubmed: 26872788
Postdoc J. 2017 Jan;5(1):14-28
pubmed: 28191478
Nat Rev Cancer. 2011 Feb;11(2):85-95
pubmed: 21258394
Nucl Med Biol. 1994 Aug;21(6):827-34
pubmed: 9234332
Nucl Med Commun. 2019 Apr;40(4):361-369
pubmed: 30664599
Clin Cancer Res. 2015 Mar 15;21(6):1258-66
pubmed: 25770293
Cell. 2018 Apr 5;173(2):400-416.e11
pubmed: 29625055
J Nucl Med. 2014 Jun;55(6):898-904
pubmed: 24711649
Eur Radiol. 2018 Oct;28(10):4350-4361
pubmed: 29721688
Cancer Res. 2018 Aug 15;78(16):4786-4789
pubmed: 29959149
Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):620-7
pubmed: 25304950
J Nucl Med. 2004 Apr;45(4):559-66
pubmed: 15073250
Nature. 2011 Apr 7;472(7341):90-4
pubmed: 21399628
Sci Rep. 2018 Jan 8;8(1):105
pubmed: 29311707
J Nucl Med. 2014 Jun;55(6):884-90
pubmed: 24752671
Nature. 2013 Sep 19;501(7467):355-64
pubmed: 24048068
AJR Am J Roentgenol. 2009 Apr;192(4):W156-60
pubmed: 19304675
Clin Colorectal Cancer. 2017 Sep;16(3):e165-e170
pubmed: 28073683
J Nucl Med. 2018 Jan;59(1):31-37
pubmed: 28588149
Phys Med Biol. 2017 Jul 7;62(13):5327-5343
pubmed: 28604368
Lung Cancer. 2014 Feb;83(2):189-96
pubmed: 24355259
Clin Cancer Res. 2015 Jan 15;21(2):249-57
pubmed: 25421725
Theranostics. 2018 Feb 15;8(7):1956-1965
pubmed: 29556367
Nat Rev Cancer. 2012 Apr 19;12(5):323-34
pubmed: 22513401
J Thorac Oncol. 2014 Jun;9(6):834-42
pubmed: 24787963
Nat Rev Clin Oncol. 2017 Dec;14(12):749-762
pubmed: 28975929